NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free BMRN Stock Alerts $87.52 -1.09 (-1.23%) (As of 01:22 PM ET) Add Compare Share Share Today's Range$87.08▼$88.6650-Day Range$83.81▼$94.0452-Week Range$76.02▼$100.38Volume307,857 shsAverage Volume1.32 million shsMarket Capitalization$16.51 billionP/E Ratio99.46Dividend YieldN/APrice Target$107.61 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioMarin Pharmaceutical alerts: Email Address BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside22.2% Upside$107.61 Price TargetShort InterestHealthy1.57% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment1.02Based on 2 Articles This WeekInsider TradingSelling Shares$5.84 M Sold Last QuarterProj. Earnings Growth49.48%From $1.92 to $2.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.94 out of 5 starsMedical Sector24th out of 939 stocksPharmaceutical Preparations Industry11th out of 433 stocks 3.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $107.61, BioMarin Pharmaceutical has a forecasted upside of 22.2% from its current price of $88.07.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.57% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 3.27%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 3.3 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioMarin Pharmaceutical this week, compared to 6 articles on an average week.Search Interest17 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.MarketBeat Follows12 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,840,586.00 in company stock.Percentage Held by InsidersOnly 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 49.48% in the coming year, from $1.92 to $2.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 100.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.13.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 100.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 200.83.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesMarch 17, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Sells $85,510.00 in StockMarch 17, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insider Henry J. Fuchs Sells 35,341 SharesMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 20, 2024 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 15, 2024 | stocknews.com3 B-Rated Biotech Stocks to Boost Your Bottom LineMarch 15, 2024 | finance.yahoo.comBMRN May 2024 90.000 callMarch 12, 2024 | prnewswire.comNew Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingMarch 11, 2024 | finance.yahoo.comBioMarin Pharmaceutical: Pioneering Innovations Are Driving Future GrowthMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 8, 2024 | finance.yahoo.comInsider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...March 7, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Andlauer Healthcare Group (OtherANDHF)March 7, 2024 | prnewswire.comBioMarin Announces Appointment of Cristin Hubbard as Chief Commercial OfficerMarch 7, 2024 | prnewswire.comBioMarin Announces Appointment of Cristin Hubbard as Chief Commercial OfficerMarch 1, 2024 | markets.businessinsider.comBuy Rating Justified by BioMarin’s Strategic R&D and Voxzogo’s Market PotentialMarch 1, 2024 | prnewswire.comBioMarin Scheduled to Participate in March Investor ConferencesFebruary 29, 2024 | seekingalpha.comBioMarin Pharmaceutical: Still Has A Lot Of Room For GrowthFebruary 27, 2024 | bizjournals.comJustice Department targets another Bay Area drug maker's sponsored testing programFebruary 27, 2024 | finance.yahoo.comDecoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT InsightFebruary 26, 2024 | msn.comDOJ reportedly subpoenas BioMarin over sponsored testing programsFebruary 26, 2024 | reuters.comBioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapiesFebruary 26, 2024 | finance.yahoo.comUPDATE 1-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapiesFebruary 26, 2024 | reuters.comBioMarin Pharma gets DOJ subpoena on certain drug testing programsFebruary 26, 2024 | stocknews.comEyeing Growth? Check Out These 3 Biotech Stock BuysFebruary 26, 2024 | markets.businessinsider.comBuy Rating for BioMarin on Strong Q4 Performance and Promising Profitability OutlookFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin on Strong Sales and Promising Growth OutlookFebruary 24, 2024 | finance.yahoo.comBioMarin Pharmaceutical Full Year 2023 Earnings: EPS: US$0.89 (vs US$0.76 in FY 2022)February 23, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)See More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$107.61 High Stock Price Target$185.00 Low Stock Price Target$78.00 Potential Upside/Downside+21.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio100.69 Forward P/E Ratio46.15 P/E Growth1.66Net Income$167.65 million Net Margins6.93% Pretax Margin7.79% Return on Equity5.01% Return on Assets3.64% Debt Debt-to-Equity Ratio0.12 Current Ratio2.51 Quick Ratio1.57 Sales & Book Value Annual Sales$2.42 billion Price / Sales6.91 Cash Flow$1.83 per share Price / Cash Flow48.36 Book Value$26.29 per share Price / Book3.37Miscellaneous Outstanding Shares188,680,000Free Float185,204,000Market Cap$16.72 billion OptionableOptionable Beta0.31 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Brian R. Mueller (Age 50)CFO & Executive VP Comp: $1.15MMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Comp: $1.18MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Comp: $1.49MMr. Alexander Hardy (Age 55)President, CEO & Director Ms. Erin BurkhartGroup VP & Chief Accounting OfficerDr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMs. Humaira SerajuddinSenior VP & Chief Marketing OfficerMs. Amy WiremanExecutive VP & Chief People OfficerMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundBought 53,087 shares on 3/21/2024Ownership: 0.028%Vanguard Group Inc.Bought 348,852 shares on 3/11/2024Ownership: 9.566%Wahed Invest LLCBought 290 shares on 3/11/2024Ownership: 0.002%SageView Advisory Group LLCBought 2,945 shares on 3/6/2024Ownership: 0.002%Jean Jacques BienaimeSold 1,000 sharesTotal: $85,510.00 ($85.51/share)View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price target for 2024? 19 Wall Street analysts have issued 12-month target prices for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they predict the company's share price to reach $107.61 in the next year. This suggests a possible upside of 22.2% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2024? BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of the year. Since then, BMRN shares have decreased by 8.7% and is now trading at $88.07. View the best growth stocks for 2024 here. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.05. The biotechnology company earned $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 5.01% and a net margin of 6.93%. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period last year, the company posted $0.11 earnings per share. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV), First Trust Innovation Leaders ETF (ILDR) and VictoryShares Nasdaq Next 50 ETF (QQQN). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of 2.600-2.800 for the period, compared to the consensus estimate of 1.960. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (9.78%), Vanguard Group Inc. (9.58%), Vanguard Group Inc. (9.57%), Dodge & Cox (7.43%), Capital Research Global Investors (5.72%) and Viking Global Investors LP (2.60%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Richard A Meier and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMRN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.